Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Common Stock Issued

Cash raised by issuing new shares.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued turns positive

Q2 FY2026 common stock issued was $3.11M, compared with -$8.64M a year earlier. Trailing-twelve-month common stock issued was $33.12M. Over 3 fiscal years it compounded at -47.0% a year.

Context

  • Common stock issued amounted to 4.0% of revenue in FY2025, down 216.7 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $3.11M or moves back toward the trailing-twelve-month quarterly average of $8.28M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.11M+33.6% QoQ
Last fiscal yearDec 2025
$38.06M-90.4% YoY
LTMJun 2026
$33.12M+345.2% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+136.0%——
1 year-90.4%——
3-year CAGR-47.0%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
38.06M USD
Year-over-year change
-90.4%
4-year CAGR
-31.2%

Common Stock Issued vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +345.2% is the 2nd highest of 6, against a peer median of +261.9%.
  • Common stock issued amounts to 2.6% of revenue for MDGL, versus a peer median of 2952.4%.
MDGL Competitors
Common Stock Issued for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€237.74M EUR+314.6%+199.8%5303.2%
ALTAltimmune, Inc.LTM Mar 2026$217.97M USD+386.8%+45.5%605458.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$120.32M USD-160.7%+442.5%601.6%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$41.68M USD-90.9%-57.9%585.3%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$33.12M USD+345.2%-47.0%2.6%
VKTXViking Therapeutics, Inc.LTM Jun 2026$3.1M USD+261.9%——
SGMTSagimet Biosciences Inc.LTM Mar 2026$275K USD—+184.0%—
Peer median (excluding MDGL) —+261.9%+184.0%2952.4%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Depreciation & Amortization405K467K527K1.1M1.51M
Deferred Income Tax(7.32M)0000
Stock-Based Compensation26.87M31.63M49.74M79.88M98.13M
Change in Working Capital30.65M37.6M(3.28M)(72.35M)(8.5M)
Accounts Receivables000(53.82M)(80.65M)
Inventory000(34.07M)(36.98M)
Accounts Payables20.36M2.45M4.21M15.56M5.28M
Other Working Capital10.29M35.15M(7.49M)(13K)103.86M
Other Non-Cash Items7.32M797K2.41M1.69M7.59M
Operating Cash Flow(183.92M)(224.86M)(324.23M)(455.57M)(189.55M)
Capital Expenditures(209K)(217K)(1.48M)(1.46M)(467K)
Acquisitions (Net)787K(3K)000
Purchases of Investments(394.12M)(143.48M)(834.44M)(1.13B)(1.05B)
Sales of Investments389.27M350.38M333.4M839.19M1.09B
Other Investing Activities(787K)3K019.09M(8.97M)
Investing Cash Flow(5.06M)206.69M(502.52M)(274.39M)32.32M
Debt Repayment050M65M0217.93M
Common Stock Issued170.21M255.38M260.19M397.49M38.06M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.03M8.07M269.93M337.58M0
Financing Cash Flow171.24M313.45M595.12M735.06M255.98M
Effect of Forex Changes000013K
Net Change in Cash(17.74M)295.28M(231.63M)5.1M98.76M
Free Cash Flow(184.13M)(225.07M)(325.71M)(457.03M)(190.02M)

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.